ClinicalTrials.gov
public full text
Public Domain
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be assessed for subjects who have permanently withdrawn from further belimumab treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Evaluate Initiation of Stalevo in Early Wearing-off#801701
- Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine#1075467
- Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study#1045555
- Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus#856232
- Care Coordination Approaches to Learning Lupus Self-management#879065
Record · ID 863922
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive